linjc16/ctgov huggingface dataset:
Applicability of 3D Printing and 3D Digital Image Reconstruction in the Planning of Complex Liver Surgery (LIV3DPRINT).

Study Overview
=================
Brief Summary
-----------------
Three-dimensional (3D) printing has gained popularity in medicine over the last decade. Once 3D printers have become more affordable, the true strength of this technique has been recognized because of its ability to obtain anatomical models based on the unique characteristics of each patient. Liver resections are challenging operations because of the complex nature of the liver and venous anatomy within the liver, so 3D imaging is a promising new tool for surgical planning.

Official Title
-----------------
Single Arm Trial of Applicability of 3D Printing and 3D Digital Image Reconstruction in the Planning of Complex Liver Surgery.

Conditions
-----------------
Liver Diseases, Surgery

Intervention / Treatment
-----------------
* Device: 3D PRINTING


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Complex liver tumors (bilobar disease, infiltration of suprahepatic veins or requiring two-time resection or intrahepatic vascular reconstruction). Preoperatively was performed, a CT scan and / or MRI of all patients were performed to document the tumor distribution, estimate remaining liver volume, and identify tumor-vessel relationships in order to know the intraoperative vascular anatomy. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: OTHER: 3D PRINTING AND 3D DIGITAL IMAGE RECONSTRUCTION<br> | Device: 3D PRINTING<br>* A 3D digital image reconstruction and a 3D printing model were performed in all patients with complex liver tumors.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surgical planing | Number of Participants susceptible of complex liver surgery as assessed by 3D printing and 3D digital image reconstruction, change from the baseline to the surgical strategy | 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Teaching for students and residents | Number of students where 3D models of digital printing and images reconstructed in 3D by using a questionnaire improve understanding about the location of lesions, liver anatomy and planning of surgery | 1 day | 
| Understanding of surgery by the patient | Number of patient who understand better liver disease and surgery strategy | 1day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
complex liver surgery, 3D printing
Evaluation of AlcoholEdu for College

Study Overview
=================
Brief Summary
-----------------
The study examined whether an online course for college freshmen (AlcoholEdu) had an effect on alcohol misuse and related problems, using a randomized controlled design with 30 universities.

Official Title
-----------------
Evaluation of AlcoholEdu: A Randomized Multi-Campus Trial

Conditions
-----------------
Alcohol Misuse

Intervention / Treatment
-----------------
* Behavioral: AlcoholEdu for College


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Colleges without an online alcohol prevention course Able to implement AlcoholEdu course for all incoming freshmen Able to provide random student samples for data collection Able to obtain IRB approval for study Exclusion Criteria: Already implementing alcohol prevention course for incoming freshmen Not able to implement online alcohol prevention course Not able to provide random student samples for data collection Not able to obtain IRB approval for study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Alcohol education and prevention<br>AlcoholEdu is an online course designed to prevent alcohol misuse and related problems among college freshmen. | Behavioral: AlcoholEdu for College<br>* Online course for college freshmen.<br>|
| No Intervention: Control<br>Control group. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Binge drinking | Frequency of binge drinking in the past 30 days | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Alcohol-related problems | Alcohol-related problems in the past 30 days | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alcohol misuse prevention, College students, Intervention and control
Evaluation of State and Shade of White Spot Lesions After Using Different Remineralizing Agents (An in Vivo Study)

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate the effect of Biomimetic remineralizing agent and resin modified glass ionomer varnish on color shade and state of white spot lesions immediately, after 3 months, and after 6 months. (An in vivo study).

Official Title
-----------------
Evaluation of State and Shade of White Spot Lesions After Using Different Remineralizing Agents (An in Vivo Study)

Conditions
-----------------
White Spot Lesion

Intervention / Treatment
-----------------
* Other: Biomimetic remineralizing agent
* Other: Resin Modified Glass Ionomer Varnish


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients included in this clinical trial were less than 30 years old. Patients with good general health. Patients who will agree to the consent and will commit to follow-up period. Fully erupted anterior teeth with no cavitated lesions. Exclusion Criteria: Patients with any systemic disease that may affect normal healing. Patient with bad oral hygiene. Tetracycline or florosis staining. Patients who could/would not participate in all times of follow-up. Untreated periodontal disease was not allowed. Active caries or defective Restorations in 6 anterior teeth. Bleaching history Patients participating in more than 1 dental study. Patient received fluoride varnish before.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Biomimetic remineralizing agent<br> | Other: Biomimetic remineralizing agent<br>* Self-assempling peptide<br>Other: Resin Modified Glass Ionomer Varnish<br>* Resin Modified Glass Ionomer Varnish<br>|
| Active Comparator: Resin modified glass ionomer varnish<br> | Other: Biomimetic remineralizing agent<br>* Self-assempling peptide<br>Other: Resin Modified Glass Ionomer Varnish<br>* Resin Modified Glass Ionomer Varnish<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| state of lesions | Digital scores | 6 months. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| shade of lesions | Digital scores | 6 months |
Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to assess the safety, tolerability and pharmacokinetics of aripiprazole tablets following oral administration to children and adolescents.

Official Title
-----------------
A Phase II Study to Test PK Tolerability in Children and Adolescents

Conditions
-----------------
Schizophrenia, Mania

Intervention / Treatment
-----------------
* Drug: Aripiprazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children and adolescents between 10-17 years, in good physical health, preferentially with a primary schizophrenia spectrum diagnosis or bipolar spectrum disorder Exclusion Criteria: History of mental retardation Any neurological disorder with the exception of Pervasive Developmental Disorder (PDD), Attention Deficit Hyperactivity Disorder (ADHD), and Tourette's Syndrome

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Aripiprazole|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pharmacokinetics,, Aripiprazole, acute mania in pediatric populations
Novel Peptide Vaccination for Patients With Advanced Renal Cell Carcinoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and CTL reaction of novel peptide vaccination for advanced renal cell carcinoma

Conditions
-----------------
Renal Cell Carcinoma

Intervention / Treatment
-----------------
* Biological: HLA-A02 restricted HIG2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: DISEASE CHARACTERISTICS advanced renal cell carcinoma which already showed resistance to standard treatments PATIENTS CHARACTERISTICS Patients who showed resistance to hormonal therapy and chemotherapy Histological diagnosis is adenocarcinoma HLA-A*0201/0206 ECOG performance status of 0 to 2 Age ≥ 20 years, ≤80 years WBC≥ 2,000/mm³, ≤12000/mm³ hemoglobin≥ 8.0g/dl Platelet count ≥ 70000/mm³ AST, ALT ≤100 IU/l Total bilirubin ≤ 1.5 mg/dl Creatinine ≤ 1.0 mg/dl PaO2≥ 70mmHg life expectancy ≥ 3months Able and willing to give valid written informed consent Exclusion Criteria: Pregnancy (women of childbearing potential: Refusal or inability to use effective means of contraception) Breastfeeding Patients willing to childbearing ( Refusal or inability to use effective means of contraception) Serious infections requiring antibiotics Concomitant treatment with steroids or immunosuppressing agent Other malignancy difficult to control. Decision of unsuitableness by principal investigator or physician-in-charge

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: HLA-A02 restricted HIG2|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with Adverse Events as a Measure of Safety and Number of Participants with Adverse Events as a Measure of Safety and Tolerability | hematological and non-hematological adverse event | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CTL reaction |  | 2 years |
HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis

Study Overview
=================
Brief Summary
-----------------
Hypothesis: In giant cell arteritis (GCA), a short initial treatment with anti-TNF may allow a faster decrease of steroids dosage and therefore avoid some of the adverse events of steroids.

Detailed Description
-----------------
The protocol consists of a SC injection of adalimumab or placebo every 2 weeks for 10 weeks added to steroids

Official Title
-----------------
HECTHOR: A Pilot Multicenter Double-blind Randomised Study of 3 Months Treatment With Humira Added to Steroids in Giant Cell Arteritis

Conditions
-----------------
Giant Cell Arteritis

Intervention / Treatment
-----------------
* Drug: adalimumab
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 50 years ACR criteria for Giant cell arteritis (HUNDER 1990) Positive Temporal artery biopsy Plus standard inclusion criteria for Humira protocols Exclusion Criteria: Prednisone treatment for a different disease at a dose >15 mg/day Corticoid treatment for GCA more than 10 days GCA treatment with prednisone > 1 mg/kg whatever period of time GCA treatment with an anti-TNF, MTX, cyclosporine, cyclophosphamide, dapsone or steroid bolus Recent, permanent or transient visual loss due to GCA and the presence of any specific visual abnormality (diplopia, hallucination) Plus standard exclusion criteria for Humira protocols

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br> | Drug: adalimumab<br>* 40 mg sc / for 3 months<br>|
| Placebo Comparator: 2<br>placebo | Drug: placebo<br>* placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the influence of an initial treatment of 3 months with adalimumab, 40 mg every other week, in the percentage of patients achieving at 6 months (week 26), a decrease in their corticosteroid treatment to a dose equal or lower than 0,1 mg/kg |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the influence of an initial treatment of 3 months with adalimumab on the total dose of corticosteroids determined by AUC (area under the curve) |  | 1 year | 
| To determine the influence of an initial treatment of 3 months with adalimumab on the percentage of patients relapsing at one year |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Giant Cell Arteritis, Placebo, Anti-TNF, Multicenter-randomized-trial, Proved GCA according to ACR criteria (HUNDER et al 1990)
Community Pharmacists Behaviour During Covid-19

Study Overview
=================
Brief Summary
-----------------
During the COVID-19 pandemic, governments issued movement restrictions and placed areas into quarantine to reduce the spread of the disease.Community pharmacists and their teams are a vital healthcare provider during the outbreak; they remain on the frontline of public health by serving as direct points of access for their patients. The retail pharmacists should provide public community, costumers and patients with right and trusted information about covid-19. They also should have role in awareness spreading regarding personnel safety and hygiene

Detailed Description
-----------------
The survey will enroll as many community pharmacists as possible in the survey portion of the study - The number of participates have no limitations, at least 50 participants. The survey will be enrolled in online google form, face to face interview & semi-structured telephone interviews if possible. The research procedures: An online survey link will include questions regarding the impact of role and behavior of retail pharmacists during covid-19 outbreak. Face to face and semi-structured interviews if possible: For those pharmacists who state that they would like to participate in an interview, a random sample will be contacted. Inclusion Criteria: Post graduated pharmacist. Community pharmacists. Exclusion Criteria: under graduated students. not pharmacist.

Official Title
-----------------
SURVEY of RETAIL PHARMACISTS KNOWLEDGE, ROLE & BEHAVIOR DURING COVID-19 VIRUS OUTBREAK

Conditions
-----------------
Covid19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Post graduated pharmacist. Community pharmacists. Exclusion Criteria: under graduated students. not pharmacist.
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| community pharmacists facing covid-19 | Evaluate the knowledge, role & behavior of retail pharmacists in facing covid-19 virus through the survey | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pharmacists/ covid-19
Coronavirus Disease (COvid-)19 REgistry on THROMBOSIS Complications

Study Overview
=================
Brief Summary
-----------------
This online-based, observational retrospective registry aims to (i) study the rate of cardiovascular events, encompassing venous thromboembolic and arterial events, in consecutive hospitalized patients with coronavirus (Covid19), (ii) investigate the prevalent use of thromboprophylaxis, (iii) describe the use of imaging tests for the detection of cardiovascular events in patients with Covid19. This will also facilitate and constitute the basis for the conduction of interventional thromboprophylaxis studies in patients with Covid19.

Official Title
-----------------
COvid-19 REgistry on THROMBOSIS Complications Associated With Hospitalization

Conditions
-----------------
Covid19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalized patients aged ≥ 18 years with a positive test for severe acute respiratory syndrome corona virus 2 (SARS-CoV2) Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fatal or non-fatal venous thromboembolism (VTE) | Rate of thromboembolic events encompassing pulmonary embolism (PE) and deep vein thrombosis (DVT) | during index hospitalization for Covid19 | 
| Fatal or non-fatal cardiovascular events | Rate of cardiovascular events encompassing stroke and myocardial infarction | during index hospitalization for Covid19 | 
| All-cause death | Rate of death from any cause | during index hospitalization for Covid19 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of cardiovascular risk factors | Baseline prevalence of cardiovascular risk factors and use of specific medications (statins, Angiotensin-converting enzyme [ACE] inhibitors) | at baseline/enrollment | 
| Length of hospitalization | Duration of inpatient stay | first index hospitalization for Covid19 | 
| Prevalent use of in-hospital thromboprophylaxis | Use of unfractionated heparin (UFH), low-molecular weight heparin (LMWH), or direct oral anticoagulants (DOAC) on/after admission due to Covid19 | during index hospitalization for Covid19 | 
| In-hospital course of D-dimer (μg/mL) | Course of laboratory biomarker | during index hospitalization for Covid19 | 
| In-hospital course of Troponin (ng/ml) | Course of laboratory biomarker | during index hospitalization for Covid19 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
thromboprophylaxis, Covid19, thromboembolism, pulmonary embolism, anticoagulation
The Effect of Surgical Incision Size on Carpal Tunnel Surgery

Study Overview
=================
Brief Summary
-----------------
This study will investigate the postoperative recovery advantages from having a smaller incision to a larger incision.

Official Title
-----------------
The Effect of Surgical Incision Size on Carpal Tunnel Surgery

Conditions
-----------------
Carpal Tunnel Syndrome

Intervention / Treatment
-----------------
* Procedure: Carpal Tunnel Release Surgery
* Procedure: Carpal tunnel release surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing open carpal tunnel release will be included in this study. Patients must have clinical evidence of Carpal Tunnel Syndrome Patients must have positive EMG results Patient selection factors include: Ability and willingness to follow instructions Patients who are able and willing to return for follow-up evaluations. Patients of all races and genders. Patients who are able to follow care instructions. Exclusion Criteria: Patients less than 18 years old Patients unwillingly or unable to comply with a rehabilitation program for carpal tunnel release who indicate difficulty or inability to return for follow-up visits prescribed by the study protocol. Patients who qualify for inclusion in the study, but refuse consent to participate in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br> | Procedure: Carpal Tunnel Release Surgery<br>* Patient will have large incision size during carpal tunnel release surgery.<br>|
| Active Comparator: 2<br> | Procedure: Carpal tunnel release surgery<br>* Patient will have a small incision size during carpal tunnel release surgery.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Function questionnaires, pain assessment questionnaires, and clinical measurements will be used to determine the outcome of this study. |  | 6 month |